ViGenCell바이젠셀
308080 · KOSDAQ · ₩308080 · 바이젠셀
- Market cap
- ₩104B
- Enterprise value
- ₩82B
- P/E
- —
- P/B
- 2.7×
- Dividend yield
- 0.0%
- ROE
- −34.2%
- Net margin
- −1,438.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.8% from the high
₩3,070Today: ₩5,000 – ₩5,200₩17,360
Returns
- 1W−5.2%
- 1M−11.4%
- 3M+5.3%
- 6M−54.2%
- YTD−48.0%
- 1Y+40.8%
- Volume today
- 82,344
- 0.9× the 20-day average
- Traded today
- ₩419M
- Listed shares
- 20,499,260
- EPS (12 months)
- −₩647
- Earnings yield −12.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumWeak-9.3% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
ViGenCell stock overview
ViGenCell (바이젠셀, KRX: 308080) is listed on KOSDAQ, in the Biotech & Pharma sector. ViroCell Inc. Its shares closed at ₩5,070 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩104B.
Key facts
- Market cap
- ₩104B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- ViroCell Inc.
Quick answers about ViGenCell
- What does ViGenCell do?
- ViroCell Inc. is a Korean cell therapy company founded in 2013 that develops and manufactures immune cell therapies, including its T-cell-based VT-EBV-N candidate for NK/T-cell lymphoma and its MDSC-based VM-GD candidate for graft-versus-host disease. The company's platforms are built on umbilical cord blood and other human blood-derived immune cells, and it operates in global new drug development and advanced regenerative medicine.
- What is the market cap of ViGenCell?
- The market capitalisation of ViGenCell was ₩104B at the close on Oct 27, 2026.
- Who are the largest shareholders of ViGenCell?
- According to the latest official filings, the largest reported holders are Ga-eun Global (15.73%, as of Mar 31, 2026); Boryung (5.00%, as of Jan 28, 2026); Kim Tae-gyu (4.89%, as of Dec 16, 2025).
- When is the next earnings report from ViGenCell?
- Korean companies rarely announce results dates in advance. Based on when ViGenCell filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own ViGenCell?
- Yes. The National Pension Service held 0.59% of ViGenCell shares as of Dec 31, 2021.
Company profile
ViroCell Inc. is a Korean cell therapy company founded in 2013 that develops and manufactures immune cell therapies, including its T-cell-based VT-EBV-N candidate for NK/T-cell lymphoma and its MDSC-based VM-GD candidate for graft-versus-host disease. The company's platforms are built on umbilical cord blood and other human blood-derived immune cells, and it operates in global new drug development and advanced regenerative medicine. It also co-develops VC-302, an iPSC-derived NK cell therapy for glioblastoma, under a technology transfer from Terabest.
Written by AI from the company's latest annual report.
- Korean name
- 바이젠셀
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 기평석
- Founded
- Feb 2013
- Listed
- Aug 2021
- Listed shares
- 20,499,260
- Fiscal year ends
- Month 12
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Investor relations (IR) eventOct 7, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Quarterly report (Mar 2026)May 14, 2026
- 5%+ holding reportMar 31, 2026
- Insider shareholding reportMar 31, 2026
Titles in Korean until English translations are added.
Also known as: ViGenCell / 바이젠셀 / 308080 / KRX:308080
Source: KRX statistical information